[Sponsored] In a webinar sponsored by Jotform, scheduled for Thursday, March 13 at 1 pm ET, panelists will discuss how health tech companies approach data automation and how practices implement it. The post Making Automation a Mainstream Function in Healthcare Practices appeared first on MedCity News.
Dr. Cunningham weighed in on a variety of subjects, including elements of technology and virtual care that burden primary care physicians, as well as technologies that are suitable for remote monitoring of older patients. The post 7 Takeaways From a Fireside Chat with Providence’s Chief of Virtual Care appeared first on MedCity News.
Healthcare affordability continues to decline as patients struggle with rising healthcare costs. Roughly half of U.S. adults report struggling to pay their medical bills. Patients are also frustrated with the lack of cost transparency, inaccurate estimates and confusion around what insurance covers and what’s owed out of pocket. When there’s a lack of understanding about…
Phase 2 data for Cargo Therapeutics’ CD22-targeting cell therapy show low durability and cases of a severe immune response, some that were classified as grade 4 or 5 serious adverse events. Cargo is discontinuing the study and shifting focus to a different cell therapy on track to begin Phase 1 testing in mid-2025. The post…
This issue brief draws from the KFF/LA Times Survey of Immigrants and other KFF analyses to highlight immigrants’ health care eligibility, healthcare use and costs, as well as their contributions to the economy and workforce.
Friends of AHRQ stress that it provides the resources necessary to determine the effectiveness of health systems delivery
This policy watch examines the USAID list of terminated awards, recently sent Congress, to examine the implications for global health programs and outstanding questions.
Editas Medicine says its in vivo gene-editing therapy for hemoglobinopathies has best-in-class potential, but the company plans to out-license or partner that program. Editas is shifting focusing to in vivo gene-editing therapies. The post Editas Medicine Seeks Partner for Ex Vivo Gene-Editing Program as Focus Turns to In Vivo R&D appeared first on MedCity News.
Rhythm Pharmaceuticals drug Imcivree met the body mass index reduction goals of a Phase 3 test in hypothalamic obesity, an acquired form of obesity stemming from dysregulation of the MC4R pathway in the hypothalamus. The engineered peptide drug is already approved for two genetically driven types of obesity. The post Rhythm Pharma Drug Lowers BMI…